1

Teva introduction Teva introduction

2014

2

Our Vision

Being the most indispensable

medicines company for the world,

executing on our obligation to

our patients, customers,

shareholders and employees

We have Profound Foundations

45,000 employees

73 manufacturing

sites

111 years in

existence

1,000 molecules

60 countries

73B tablets and

capsules per annum

55,000+ SKUs

$5.01 2013 EPS

$20.3B 2013 revenues

Core Strengths

Leading healthcare provider

Balanced business

model

Integrated

R&D

Manufacturing strengths

Partnering experience

Go-to-market capabilities

Entrepreneurial employees and

culture

A truly global operations network

Financial Growth

* Operating income and net income are non-GAAP results

2013 2012

20,314 20,317 Sales $M

5,198 5,715 Operating Income $M

4,255 4,671 Net Income $M

Expansion of wealth and health care access

Rising health care costs

Our World Changes

Aging population

Increasing competition in generics

Shift in disease patterns

Rising bar for product innovation

Complicated, expanding global market

Branded generics business

R&D capabilities

Impact healthcare system

Pipeline of high-value products

Generics: a great future

Global

Sustainable high-barrier to entry

Rapid growth

Dramatically enhanced in selected areas

Research and development

Develop the most competitive

and focused pipeline

to address unmet patient needs

in a highly differentiated way

to drive the growth of Teva

Life and science intimately connected … that’s uniquely Teva

NTEs High value

generics

Focused specialty portfolio

NTEs - The Future of Teva R&D

NEW THERAPEUTIC ENTITY Known molecule that is formulated, delivered, or used in a novel way to

address specific patient needs

Specialty medicines: focus and build leadership

CNS

Respiratory

New Therapeutic Entities (NTEs)

Oncology, Women's Health, Biologics

Protect and expand MS franchise

Build products and pipeline

Invest in capabilities and pipeline

Continue global expansion

Capitalize on unique Teva interface

of Generics and Specialty

Selectively invest

17 17

OTC Business

World’s leading provider of medicines Portfolio of leading brands

Best-in-class

Consumer understanding

Brand-building

Advertising scale

Strong product development and

production capabilities World’s leading brand-

builder

+

PGT Consumer Healthcare: JV with P&G leverages value in existing OTC business

18

Teva Global Community Statement

Teva is committed to improving global healthcare. We recognize our responsibility to invest in and support the communities we serve.

We focus our involvement on the communities in the countries in which we operate, through a range of activities that enhance access to medicines and contribute to the wellbeing of the communities in which we live.

We are proud of our many employees who volunteer in the community and we support them in a range of ways.

19

20